MSN Laboratories develops Covid drug “Faripiravir 800 mg”


Hyderabad: In bid to address the shortage of the antiviral drug, the Hyderabad-based India’s leading pharma company, MSN Laboratories Pvt. Ltd. (MSN Labs), has developed Faripiravir to treat mild and moderate Covid-19 flu.

The drugwas launched on Wedesday is branded generic, Favilow 800 mg. The higher strength Favilow 800 mg is priced at Rs 144 per tablet and will be available across pharmacies. The field team of MSN Labs is also helping out with free home delivery in over 170 cities in coordination with local retail chemists for patient convenience.

Dr MSN Reddy, CMD – MSN Group said, “In the light of increasing Covid-19 cases in India, affordable treatment options are the need of the hour to flatten the curve. We are sure that our product Favilow 800 would help support the nation’s efforts in overcoming the Covid crisis.”

He claimed that MSN had launched this world’s most affordable branded generic of Favipiravir, Favilow, in August last year, in the strengths of 200 and 400 mg. He also claims the higher strength will improve patient compliance and experience by effectively reducing the number of tablets a patient requires per day. The launch would also address the shortages and issues faced by the patients in procuring the Covid-19 drug.

Company’s Executive Director, Bharat Reddy, added, “MSN is currently manufacturing more than 1 lac dosage regimen (5 lakh *strips of different strengths of FAVILOW) for the treatment of COVID-19 in last 15 days, and are scaling up the manufacturing volumes to 6-8 lacs dosage regimen (30 lakh strips of different strengths of FAVILOW) by next month.”

The higher strength of Favipiravir 800 mg from MSN has been approved by the Drug Controller General of India (DCGI). MSN successfully developed the active pharmaceutical ingredient (API) and the formulation for FAVILOW 800 mg in its in-house R&D and manufacturing units. The API & FDF of Favilow matches to the International quality standards.

Senior Vice President Domestic Formulation of the Company,Ashish Gupta said, “The MSN team is reaching out to the doctors, hospitals and patients across the country to ensure that Favilow is easily accessible and the current shortage can be addressed efficiently. The Favilow helpline initiative has already served more than 1000 patients by making the drug available from near by chemists.”

As the country battles an explosive rise in Covid-19 cases, the availability of antivirals like Remdesivir, Oseltamivir and other key Covid-related drugs is becoming a challenge.

As part of the Covid treatment range, MSN has already launched Oseltamivir 75 mg capsules another anti-viral medication under the brand name ‘’OSELOW’’. For availability, please contact MSN Covid Helpline @ 91005 91030 or email to